anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A good adjuvant is needed for exploiting a nontoxic efficient vaccine. Research shows that: invading process of fowl mycobacterium is finished by depending combination of fibronectin-binding protein (FBP) and fibronectin of intestine epidermal M cells when fowl mycobacterium infects people and livestock, and strong immunization reaction can be inducted and generated by purified FBP immunization animals. Therefore, the protein can be used to exploit the nontoxic efficient vaccines. A conventional method comprises: mixing the antigen protein of pathogen and FBP for animal immunization. But the generation of a large amount of pathogen antigen protein and FBP needs a molecular biology means which is tedious in process and expensive in cost. Therefore, the hydatid TSP3 gene and the FBP gene are linked via GSGGSG splice, and then are introduced into pBAD/Thio-TOPO carrier for fusion expression. Mice immunization experiments of fusion protein show that: the technology helps to substantially improve immune effect, save cost and provide new thinking for exploiting effective anti-echinococcosis vaccine.
Secondary hyperparathyroidism (SHPT) is a frequent complication in patients with chronic kidney disease (CKD) stage 5 receiving dialysis. SHPT is an adaptive response to CKD and is characterized by an elevation in parathyroid hormone (PTH) and consecutively high calcium levels. Elevations in calcium levels, phosphate levels, and PTH are correlated with CKD disease progression as well as development or aggravation of cardiovascular impairment. Many CKD patients cannot be treated well with Vitamin D analogues because of effects on calcium. Hypercalcemia is a well - known factor for cardiac disease. No data are available in Austria for a cohort with cardiac disease treated with Zemplar (paricalcitol IV).
Colorectal Health Research Champion (CHRC) trainees receive 5 education sessions on colorectal cancer, clinical research, biospecimen donation, ethics, and presentation skills. The CHRCs will invite others in their social networks to present to them this educational information, following the train the trainer model of health education.
1291377 Depilatory compositions L'OREAL 4 Feb 1970 [4 Feb 1969] 5284/70 Heading A5B Depilatory compositions comprising a flexible support, having on at least one face thereof a composition having a pH greater than 7 and comprising an organic thiol, an adhesive and, if necessary, a basic substance in an amount sufficient to bring the pH of the composition to above 7, said adhesive being (a) one capable of adhering to the skin and to hair sufficiently to allow the hair to be removed, after the thiol has acted on the hair, by the depilatory composition and (b) one whose adhesive forces to the support are greater than the adhesive forces to the skin. The support may comprise a sheet of paper or of a synthetic resin, which may or may not be perforated, or of a textile material. Alternatively the support may be prepared in situ on the skin and the depilatory composition contains a film-forming product (such as a wax or polymer which is soluble in a solvent also present) e.g. an acrylate or a methacrylate, or a polymerisable monomer; such composition may be in the form of a solution, cream, gel or an aerosol. The adhesive may be ethyl cyanacrylate and the organic thiol may be an alkali metal mercapto-carboxylic acid salt such as a sodium, potassium or lithium salt of thioglycollic acid, or of &alpha;- or #-mercapto propionic acid. The film-forming product may also constitute the adhesive. The composition may have a pH from 10 to 12 and may also contain a wetting agent such as an alkaline earth metal salt; a swelling agent such as urea, thiourea, melamine, guanidine or an alkali metal thiocyanate; and/or a hair-removing accelerator such as an alkali metal or alkaline earth metal thiocyanate, melamine or dicyandiamide. The adhesive substance and/or the basic substance giving the composition a pH greater than 7 and/or optionally the film-forming product and/or hair-removing accelerator are present in the depilatory in micro-encapsulated form, the walls of the micro-capsules being sufficiently thin to be able to break under the effect of crushing. A preferred encapsulating material is a polyethylene having a melting point from 110‹ to 140‹C and the microcapsules may be present on the support or may be contained in an aerosol composition.
STUDY OBJECTIVE: Premenstrual syndrome (PMS), dysmenorrhea, and abnormal uterine bleeding are frequent gynecological problems in adolescent girls. Studies show that sleep disorders and menstrual cycle irregularities are common conditions and indicate that they may occur together. Studies on the relationship between sleep quality and menstruation are mostly available for late adolescents (17 years and older) and young adult age groups. Our study aims to evaluate this relationship in adolescents aged 12-18.
METHODS: A survey study was structured and consisted of 4 sections. The first section includes anthropometric measurements and medical history of the participants; the second section includes "menstruation and menstruation symptoms history"; the third section includes "The Sleep Quality Scale and Sleep Variable Questionnaire"; and the fourth section includes the "Premenstrual Syndrome Assessment Scale" (PMSAS). Our survey was applied to those who visited the adolescent medicine outpatient clinic.
RESULTS: The Sleep Quality Scale score was significantly lower in those with high PMSAS scores (P < .001). The participants who had dysmenorrhea and experienced other symptoms during menstruation had significantly lower SQS scores and sleep efficiency (SE) (P < .001). There was no significant difference between heavy menstrual bleeding, defined as lasting more than 7 days, requiring more than 5-6 pads/tampons per day, and SE/quality (P > .05).
CONCLUSION: According to our study, dysmenorrhea and the presence of PMS may negatively affect the sleep quality of adolescents. Health professionals dealing with young people should take into account the effects of menstrual problems on sleep quality and offer appropriate support/treatment options.
The goal of this protocol is to optimize new technology that enables Magnetic Resonance Imaging (MRI) at a static magnetic field strength of 7 Tesla (7T). Techniques will be developed for anatomical, functional, and spectroscopic MRI that can take advantage of this high field. Routine clinical MRI has been performed at 1.5T for over twenty years and over the past ten years MRI at 3-4T has demonstrated large increases in sensitivity and is beginning to find widespread application for functional imaging of the brain and clinical research. Since the late 1990's it has been possible to produce magnets with field strengths between 7-9T large enough for human use. Indeed there are presently two sites with 7T and one with 8T MRI that have begun to produce exciting images. These initial results confirm that MRI can be performed safely at these high field strengths and that the whole range of MRI experiments can be performed. We will take delivery of the first 7T MRI system produced by General Electric, the leading producer of MRI equipment, sometime in late 2002/early 2003.

Compared to 3-4T, the 7T scanner is expected to improve sensitivity by a factor of two and improve contrast to noise for functional imaging and spectroscopy by a factor of two - four. However, realizing these goals for routine practice and whole brain coverage will require technical developments and integrating these developments into optimized data acquisition and processing strategies. Therefore, we plan to extend parallel imaging strategies, currently becoming available for 3T MRI, to 7T in order to realize the full gain in sensitivity and apply these techniques to obtain high resolution anatomical MRI, generate high temporal and spatial resolution perfusion images using arterial spin labeling techniques, generate high-temporal and spatial resolution functional images of the brain using blood oxygenation (BOLD) and perfusion based techniques, and test the usefulness of 7T for spectroscopic studies of metabolites of the brain. All of these developments will be performed on normal, healthy volunteers.
Tinnitus is known to affect 10-15 % of the population, severely impacting 1-2 % of those afflicted. Canonically, tinnitus is generally a consequence of peripheral auditory damage resulting in maladaptive plastic changes in excitatory/inhibitory homeostasis at multiple levels of the central auditory pathway as well as changes in diverse nonauditory structures. Animal studies of primary auditory cortex (A1) generally find tinnitus-related changes in excitability across A1 layers and differences between inhibitory neuronal subtypes. Changes due to sound-exposure include changes in spontaneous activity, cross-columnar synchrony, bursting and tonotopic organization. Few studies in A1 directly correlate tinnitus-related changes in neural activity to an individual animal's behavioral evidence of tinnitus. The present study used an established condition-suppression sound-exposure model of chronic tinnitus and recorded spontaneous and driven single-unit responses from A1 layers 5 and 6 of awake Long-Evans rats. A1 units recorded from animals with behavioral evidence of tinnitus showed significant increases in spontaneous and sound-evoked activity which directly correlated to the animal's tinnitus score. Significant increases in the number of bursting units, the number of bursts/minute and burst duration were seen for A1 units recorded from animals with behavioral evidence of tinnitus. The present A1 findings support prior unit recording studies in auditory thalamus and recent in vitro findings in this same animal model. The present findings are consistent with sensory cortical studies showing tinnitus- and neuropathic pain-related down-regulation of inhibition and increased excitation based on plastic neurotransmitter and potassium channel changes. Reducing A1 deep-layer tinnitus-related hyperactivity is a potential target for tinnitus pharmacotherapy.
INTRODUCTION: Some experts recommend that ambulant hypothermic patients should be rewarmed, fed, and not permitted to exercise for 30 min because of concerns that afterdrop can cause cardiac instability. We investigated the outcome of ambulant hypothermic patients in a case series from mountain rescue teams in Great Britain.
METHODS: A questionnaire was used to collect information on a series of adult patients with a clinical diagnosis of mild hypothermia. All patients were alert on the AVPU scale and evacuated by walking from the mountain. The outcome measures were survival or a change in management because of medical deterioration during evacuation.
RESULTS: A series of 108 eligible cases were reported over a 5-year period. When rescuers arrived on the scene, 98 (91%) patients were stationary, and 10 (9%) were still mobile. Thirty-eight (39%) of the stationary cases were walked immediately off the mountain without any on-scene delay. In the remaining 60 (61%) stationary cases, the decision was taken to delay evacuation to provide food, drinks, and additional clothing. In 3 cases, the use of heat packs indicated an intention to actively rewarm. In cases where the on-scene time was reported, 27 (79%) were known to be mobile again within 20 min. All patients survived, and no adverse medical events occurred in all 108 cases.
CONCLUSIONS: In this study, no adverse events occurred because of immediate mobilization, suggesting that in these cases, there appears to be minimal risk of early activity.
This study is a opened,randomized and controlled phase Ⅳ clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of sequential vaccination of two EV71 inactived vaccines in healthy infants aged 6-35 months. EV71 inactived vaccines(Vero cells）was manufactured by Sinovac Biotech Co., Ltd and EV71 inactived vaccines(Human diploid cells）was manufactured by Institute of Medical Biology Chinese Academy of Medical Sciences.300 infants aged between 6-35 months will be randomly assigned into experimental group in the ratio 1:1:1:1.The experimental group 1 received two doses EV71 inactived vaccines(Vero cells）on day 0 and 30. The experimental group 2 received two doses EV71 inactived vaccines (Human diploid cells）on day 0 and 30. The experimental group 3 received one dose EV71 inactived vaccines (Vero cells）on day 0 and one dose EV71 inactived vaccines (Human diploid cells）on day 30.The experimental group 4 received one dose EV71 inactived vaccines (Human diploid cells）on day 0 and one dose EV71 inactived vaccines (Vero cells）on day 30. To evaluate the immunogenicity of the vaccine, venous blood will be collected for the EV71 neutralizing antibody detection prior to vaccination and 30 days after the 2nd dose vaccination.
Aspects of the disclosure relate to a method for modifying a chimeric antigen receptor (CAR)-T cell comprising contacting the CAR-T cell ex vivo with an inhibitor, wherein the inhibitor comprises an inhibitor of PI3K, AKT, mTOR, c-MYC, SREBP, or combinations thereof. Further aspects relate to a CAR-T cell or cells made by the method of the disclosure. Also described are populations of CAR-T cells made by methods of the disclosure or derived from cells of the disclosure. The term "derived" refers to a cell that is the progeny of the cell from which it is derived. It may have further modifications or may be unmodified from the parent cell. Further aspects relate to a method for treating a subject comprising administering the cell or cells of the disclosure. Compositions comprising an inhibitor of PI3K, AKT, mTOR, c-MYC, SREBP, or combinations thereof and CAR-T cells are also disclosed.
Diabetic nephropathy (DN) is a serious concern in patients with diabetes mellitus. Prolonged hyperglycemia induces oxidative damage, chronic inflammation, and build-up of extracellular matrix (ECM) components in the renal cells, leading to kidney structural and functional changes. Imperatorin (IMP) is a naturally occurring furanocoumarin derivative with proven antioxidative and anti-inflammatory properties. We investigated whether IMP could improve DN and employed high glucose (HG)-induced HK-2 cells and high-fat diet-fed streptozotocin (HFD/STZ)-generated DN experimental model in C57BL/6 mice. In vitro, IMP effectively reduced the HG-activated reactive oxygen species generation, disturbance in the mitochondrial membrane potential (MMP) and epithelial-to-mesenchymal transition (EMT)-related markers, and the transforming growth factor (TGF)-β and collagen 1 expression in HK-2 cells. In vivo, we found an elevation of serum creatinine, kidney histology alterations, and collagen build-up in the kidneys of the DN control group. Also, we found an altered expression of EMT-related markers, upregulation of the TGF-β/Smad2/3 axis, and elevated pro-inflammatory molecules, TNF-α, IL-1β, IL-18 and phospho-NF-kB (p65) in the DN control group. IMP treatment did not significantly reduce the blood glucose level compared to the DN control group. However, IMP treatment effectively improved renal damage by ameliorating kidney histological changes and serum renal injury markers. IMP treatment restored renal antioxidants and exhibited anti-inflammatory effects in the kidneys. Moreover, the abnormal manifestation of EMT-related attributes and elevated levels of TGF-β, phospho-Smad2/3, and collagen 1 were also normalized in the IMP treatment group. Our findings highlight that IMP may be a potential candidate for treating DN.
Patients who meet the inclusion criteria will be enrolled into the study either by the attending physician in the Emergency Department at BC Children's hospital or by one of the study investigators. They will be randomly assigned to one of three treatment groups: above elbow cast, long arm splint, or tape. After being treated, patients will be required to fill in a daily pain diary describing their level of pain and how much analgesia they are requiring. They will also be followed by regular phone calls to track any complications of treatment (e.g. loosening or shifting of cast/ splint/ tape, any skin breakdown, etc.). Patients will be seen for follow-up at three weeks post-injury in the Orthopedics Clinic at BCCH to have radiographs repeated, finish their treatment, and hand in their pain diaries.
A system for image capture and analysis that includes a database storing a plurality of first, second and third medical codes. The first medical codes are associated with diagnostic test identifiers, the second medical codes are associated with a test result and the third medical codes are associated with a recommended pharmaceutical product. A server is disposed on a network that includes a program therein for configuring the server to receive from a mobile device an image of a retail testing product. The server detects a diagnostic test identifier of the retail testing product in the image. The diagnostic test identifier identifies a type of test performed by the retail testing product. The server retrieves a first medical code from a database associated with the diagnostic test identifier and the retail testing product. The server performs digital image processing on the image of the retail testing product and determines test results indicated by the digitally processed image of the retail testing product. The server retrieves a second medical code from the database that is associated with the test results determined from the digitally processed image. The server determines a recommended pharmaceutical product useful in treatment of at least one medical condition associated with the retail testing product responsive to the test results and retrieves a third medical code from the database associated with the recommended pharmaceutical product. Finally, the server transmits the first medical code associated with the retail test product, the second medical code associated with the test results, and the third medical code associated with the recommended pharmaceutical product to a healthcare entity.
Absorption and Bioavailability. After subcutaneous injection of insulin glargine in healthy subjects and in patients with diabetes, the insulin serum concentrations indicated a slower, more prolonged absorption and a relatively constant concentration/time profile over 24 hours with no pronounced peak in comparison to NPH insulin. Serum insulin concentrations were thus consistent with the time profile of the pharmacodynamic activity of insulin glargine.

After subcutaneous injection of 0.3 Units/kg insulin glargine in patients with type 1 diabetes, a relatively constant concentration/time profile has been demonstrated. The duration of action after abdominal, deltoid, or thigh subcutaneous administration was similar.

Metabolism. A metabolism study in humans indicates that insulin glargine is partly metabolized at the carboxyl terminus of the B chain in the subcutaneous depot to form two active metabolites with in vitro activity similar to that of insulin, M1 (21A-Gly-insulin) and M2 (21A-Gly-des-30B-Thr-insulin). Unchanged drug and these degradation products are also present in the circulation.

Special Populations

Age, Race, and Gender. Information on the effect of age, race, and gender on the pharmacokinetics of LANTUS is not available. However, in controlled clinical trials in adults (n=3890) and a controlled clinical trial in pediatric patients (n=349), subgroup analyses based on age, race, and gender did not show differences in safety and efficacy between insulin glargine and NPH insulin [see Clinical Studies (14)].

Smoking. The effect of smoking on the pharmacokinetics/pharmacodynamics of LANTUS has not been studied. 

Pregnancy. The effect of pregnancy on the pharmacokinetics and pharmacodynamics of LANTUS has not been studied [see Use in Specific Populations (8.1)].

Obesity. In controlled clinical trials, which included patients with Body Mass Index (BMI) up to and including 49.6 kg/m2, subgroup analyses based on BMI did not show differences in safety and efficacy between insulin glargine and NPH insulin [see Clinical Studies (14)].

Renal Impairment. The effect of renal impairment on the pharmacokinetics of LANTUS has not been studied. However, some studies with human insulin have shown increased circulating levels of insulin in patients with renal failure. Careful glucose monitoring and dose adjustments of insulin, including LANTUS, may be necessary in patients with renal impairment [See Warnings and Precautions (5.5)].

Hepatic Impairment. The effect of hepatic impairment on the pharmacokinetics of LANTUS has not been studied. However, some studies with human insulin have shown increased circulating levels of insulin in patients with liver failure. Careful glucose monitoring and dose adjustments of insulin, including LANTUS, may be necessary in patients with hepatic impairment [See Warnings and Precautions (5.6)].
Acupoint catgut embedding (ACE) is a safe and effective method for treating obesity. However, how it modulates intestinal flora and adiponectin remains unclear. We employed 16s rRNA sequencing technology to investigate ACE induced changes in intestinal flora and its association with adiponectin in subjects who received real (n = 41) and Sham (n = 41) stimulation. After treatment, the ACE group's body weight, BMI, WC, HC, WHtR, and WHR were significantly lower than those of the Control group (p < .01), there was statistically significant differences in ADPN between the two groups (p < .01). ACE reduces the species abundance and increased the diversity and differences of the gut microbiota in perimenopausal patients with central obesity. Most notably, there was an increase in Kosakonia and Klebsiella after ACE treatment in the patients. Significant negatively correlations were found between body weight/waist circumference and adiponectin. Increases in Klebsiella and Kosakonia were positively correlated with adiponectin, and were negatively correlated with body weight/waist circumference. Our results showed increases in Klebsiella and Kosakonia were correlated with body weight/waist circumference and adiponectin. These findings suggest that ACE-induced weight loss is probably in part associated with increases in adiponectin, Klebsiella and Kosakonia.Trial re-registration: www.chictr.org.cn, ID: ChiCTR2400087718, Registration Date: August 2nd 2024.
The DEMA-Pro intervention will be administrated. Subjects will attend six weekly, 1-hour telephone sessions.
This invention discloses the preparation and the application of Grain Worm for treating diabetes or regulating blood insulin level. The Grain Worm can be in the form of dry powder, tincture, or extracts by itself or in a compound. Grain Worm regulates the blood insulin levels and the human blood glucose level for treating diabetes. It has been discovered that Grain Worm can effectively treat diabetes in humans through reducing insulin resistance and improving the β-cell function. The effect of this agent can last a long period of time (2-5 years). This is the first major discovery of using Grain Worm in treating diabetes.